Romidepsin

Summary

Romidepsin (CHEMBL343448) is an approved protein antineoplastic agent (ATC L01XH02) targeting HDAC2, HDAC3, and HDAC6; indicated across 47 conditions including primary cutaneous t-cell non-hodgkin lymphoma and peripheral t-cell lymphoma, not otherwise specified.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Protein
• ATC class: L01XH02
• Targets: 9 (HDAC2, HDAC3, HDAC6…)
• Indications: 47 conditions
• Clinical trials: 94
• Chemistry: 540.7 Da · C24H36N4O6S2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL343448
Name	Romidepsin
Type	Protein
Max phase	4
FDA approved	yes
PubChem CID	5352062
ChEBI	CHEBI:61080
ATC	L01XH02
Molecular formula	C24H36N4O6S2
Molecular weight	540.7
InChIKey	OHRURASPPZQGQM-GCCNXGTGSA-N

SMILES: C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C

IUPAC name: (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone

ChEBI definition: A cyclodepsipeptide consisting of the cyclic disulfide of (2Z)-2-aminobut-2-enoyl, L-valyl, (3S,4E)-3-hydroxy-7-sulfanylhept-4-enoyl, D-valyl and D-cysteinyl residues coupled in sequence and cyclised head-to tail.

Pharmacological roles (ChEBI): antineoplastic agent, EC 3.5.1.98 (histone deacetylase) inhibitor.

Also known as: Chromadax, Depsipeptide, FK-228, FK228, FR-901228, FR901228, Istodax, NSC-630176, Romidepsin, Romidepsina, Romidepsine, NSC754143

Patent coverage: 5,445 distinct patent families (12,963 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
HDAC2	histone deacetylase 2	Inhibition	10.42	3.1%	Q92769
HDAC3	histone deacetylase 3	Inhibition	9.82	95.1% (common-essential)	O15379
HDAC6	histone deacetylase 6	Inhibition	8.02	0%	Q9UBN7
HDAC8	histone deacetylase 8	Inhibition	9.82	4.9%	Q9BY41
HDAC9	histone deacetylase 9	Inhibition	5.96	0%	Q9UKV0
HDAC1	histone deacetylase 1	Inhibition	11.82	4.5%	Q13547
HDAC4	histone deacetylase 4	Inhibition	7.69	3.1%	P56524
HDAC5	histone deacetylase 5	Inhibition	6.26	0.5%	Q9UQL6
HDAC7	histone deacetylase 7	Inhibition	5.9	4.2%	Q8WUI4

Broader ChEMBL bioactivity targets: 21 (assay-derived). Sample: Bromodomain-containing protein 4, Histone deacetylase 3, Protein deacetylase HDAC6, Histone deacetylase 2, Thromboxane A2 receptor, Histone deacetylase, Histone deacetylase 3/Nuclear receptor corepressor 2 (HDAC3/NCoR2), Histone deacetylase 5, Histone deacetylase 7, Protein deacetylase HDAC6.

Bioactivity

ChEMBL activities: 132 potent at pChembl ≥ 5 of 136 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HDAC2	10.42	Ki	0.04	nM	CHEMBL_ACT_13431789
HDAC2	10.42	Ki	0.04	nM	CHEMBL_ACT_3389934
HDAC8	9.82	Ki	0.15	nM	CHEMBL_ACT_13431777
HDAC3	9.82	Ki	0.15	nM	CHEMBL_ACT_13431782
HDAC3	9.82	Ki	0.15	nM	CHEMBL_ACT_3389935
HDAC8	9.82	Ki	0.15	nM	CHEMBL_ACT_3389940
HDAC1	9.7	IC50	0.2	nM	CHEMBL_ACT_10981405
HDAC11	9.52	IC50	0.3	nM	CHEMBL_ACT_15136657
HDAC11	9.52	IC50	0.3	nM	CHEMBL_ACT_22975017
HDAC11	9.52	IC50	0.3	nM	CHEMBL_ACT_25992126
HDAC1	9.51	IC50	0.31	nM	CHEMBL_ACT_14550859
HDAC2	9.33	Ki	0.47	nM	CHEMBL_ACT_25472544
Q9Z2V5	9.2	IC50	0.62	nM	CHEMBL_ACT_15002559
HDAC1	9.1	IC50	0.8	nM	CHEMBL_ACT_15136621
HDAC1	9.06	Ki	0.88	nM	CHEMBL_ACT_25472541
HDAC10	9.05	IC50	0.9	nM	CHEMBL_ACT_15136660
HDAC3	9.05	IC50	0.9	nM	CHEMBL_ACT_24420366
HDAC2	9	IC50	1	nM	CHEMBL_ACT_10981401
HDAC1	9	IC50	1	nM	CHEMBL_ACT_12074993
HDAC1	9	IC50	1	nM	CHEMBL_ACT_15002545
HDAC2	9	IC50	1	nM	CHEMBL_ACT_15136618
HDAC3	9	IC50	1	nM	CHEMBL_ACT_18784792
HDAC10	9	IC50	1	nM	CHEMBL_ACT_22974842
HDAC1	9	IC50	1	nM	CHEMBL_ACT_22974886
HDAC2	9	IC50	1	nM	CHEMBL_ACT_22974890
HDAC3	9	IC50	1	nM	CHEMBL_ACT_22974894
HDAC1	9	IC50	1	nM	CHEMBL_ACT_25992086
HDAC2	9	IC50	1	nM	CHEMBL_ACT_25992090
HDAC3	9	IC50	1	nM	CHEMBL_ACT_25992094
HDAC10	9	IC50	1	nM	CHEMBL_ACT_25992122

Target pathways

Aggregated over 9 target gene(s): HDAC2, HDAC3, HDAC6, HDAC8, HDAC9, HDAC1, HDAC4, HDAC5, HDAC7.

Top Reactome pathways

71 total, by targets touching each:

Pathway	Targets	Genes
NOTCH1 Intracellular Domain Regulates Transcription	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 PEST Domain Mutants	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Notch-HLH transcription pathway	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Differentiation of naive CD4+ T cells to T helper 2 cells (Th2 cells)	9	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Regulation of PTEN gene transcription	5	HDAC1, HDAC2, HDAC3, HDAC5, HDAC7
HDACs deacetylate histones	4	HDAC1, HDAC2, HDAC3, HDAC8
p75NTR negatively regulates cell cycle via SC1	3	HDAC1, HDAC2, HDAC3
SUMOylation of chromatin organization proteins	3	HDAC1, HDAC2, HDAC4
Regulation of MECP2 expression and activity	3	HDAC1, HDAC2, HDAC3
STAT3 nuclear events downstream of ALK signaling	3	HDAC1, HDAC2, HDAC3
ERCC6 (CSB) and EHMT2 (G9a) positively regulate rRNA expression	2	HDAC1, HDAC2
NoRC negatively regulates rRNA expression	2	HDAC1, HDAC2
Regulation of TP53 Activity through Acetylation	2	HDAC1, HDAC2
RNA Polymerase I Transcription Initiation	2	HDAC1, HDAC2
RUNX2 regulates osteoblast differentiation	2	HDAC3, HDAC6
MECP2 regulates neuronal receptors and channels	2	HDAC1, HDAC2
FOXO-mediated transcription of oxidative stress, metabolic and neuronal genes	2	HDAC1, HDAC2
Potential therapeutics for SARS	2	HDAC1, HDAC2
Negative Regulation of CDH1 Gene Transcription	2	HDAC1, HDAC2
Factors involved in megakaryocyte development and platelet production	2	HDAC1, HDAC2
Regulation of endogenous retroelements by KRAB-ZFP proteins	2	HDAC1, HDAC2
Transcriptional regulation of brown and beige adipocyte differentiation by EBF2	2	HDAC1, HDAC2
Regulation of endogenous retroelements by Piwi-interacting RNAs (piRNAs)	2	HDAC1, HDAC2
NuRD complex assembly	2	HDAC1, HDAC2
Interaction of NuRD complexes with transcription factors	2	HDAC1, HDAC2
Transcription of E2F targets under negative control by DREAM complex	1	HDAC1
Transcription of E2F targets under negative control by p107 (RBL1) and p130 (RBL2) in complex with HDAC1	1	HDAC1
G0 and Early G1	1	HDAC1
PPARA activates gene expression	1	HDAC3

Dominant GO biological processes

GO term	Targets
chromatin organization	9
negative regulation of transcription by RNA polymerase II	8
negative regulation of DNA-templated transcription	8
positive regulation of transcription by RNA polymerase II	5
protein deacetylation	5
epigenetic regulation of gene expression	5
negative regulation of gene expression, epigenetic	5
negative regulation of macromolecule biosynthetic process	4
chromatin remodeling	3
positive regulation of cell population proliferation	3
response to xenobiotic stimulus	3
heterochromatin formation	3
circadian regulation of gene expression	3
positive regulation of intracellular estrogen receptor signaling pathway	3
negative regulation of apoptotic process	3

Indications & clinical

Indications

47 indications (6 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
primary cutaneous T-cell non-Hodgkin lymphoma	4	MONDO:0000607	EFO:0002913
peripheral T-cell lymphoma, not otherwise specified	4	MONDO:0004964	EFO:0000211
neoplasm	4	MONDO:0005070	EFO:0000616
mature T-cell and NK-cell non-Hodgkin lymphoma	4	MONDO:0000430	MONDO:0000430
T-cell non-Hodgkin lymphoma	4	MONDO:0015760	MONDO:0015760
angioimmunoblastic T-cell lymphoma	3	MONDO:0004977	EFO:0000255
lymphoma	3	MONDO:0005062	EFO:0000574
plasma cell myeloma	2	MONDO:0009693	EFO:0001378
melanoma	2	MONDO:0005105	EFO:0000756
B-cell chronic lymphocytic leukemia	2	MONDO:0004948	EFO:0000095
HIV infectious disease	2	MONDO:0005109	EFO:0000180
acute promyelocytic leukemia	2	MONDO:0012883	EFO:0000224
diffuse large B-cell lymphoma	2	MONDO:0018905	EFO:0000403
thyroid gland follicular carcinoma	2	MONDO:0005034	EFO:0000501
gastric adenocarcinoma	2	MONDO:0005036	EFO:0000503
thyroid gland papillary carcinoma	2	MONDO:0005075	EFO:0000641
small cell lung carcinoma	2	MONDO:0008433	EFO:0000702
non-small cell lung carcinoma	2	MONDO:0005233	EFO:0003060
male breast carcinoma	2	MONDO:0005628	EFO:0006861
mantle cell lymphoma	2	MONDO:0018876	EFO:1001469
ovarian cancer	2	MONDO:0008170	MONDO:0008170
follicular lymphoma	2	MONDO:0018906	MONDO:0018906
anaplastic large cell lymphoma	2	MONDO:0020325	EFO:0003032
gastric neoplasm	2	MONDO:0021085	MONDO:0001056
colorectal neoplasm	2	MONDO:0005335	MONDO:0005575
breast neoplasm	2	MONDO:0021100	MONDO:0007254
anaplastic astrocytoma	1	MONDO:0016684	EFO:0002499
anaplastic oligodendroglioma	1	MONDO:0016696	EFO:0002501
gliosarcoma	1	MONDO:0016681	EFO:1001465
Hodgkins lymphoma	1	MONDO:0004952	EFO:0000183
leukemia	1	MONDO:0005059	EFO:0000565
liposarcoma	1	MONDO:0005060	EFO:0000569
exocrine pancreatic carcinoma	1	MONDO:0005192	EFO:0002618
triple-negative breast carcinoma	1	MONDO:0005494	EFO:0005537
non-Hodgkin lymphoma	1	MONDO:0018908	EFO:0005952
Sezary syndrome	1	MONDO:0017844	EFO:1000785
inflammatory breast carcinoma	1	MONDO:0006804	EFO:1000984
mycosis fungoides	1	MONDO:0009691	EFO:1001051
glioblastoma	1	MONDO:0018177	EFO:0000519
brain neoplasm	1	MONDO:0021211	EFO:0003833
pancreatic ductal adenocarcinoma	1	MONDO:0005184	MONDO:0005184
hematopoietic and lymphoid system neoplasm	1	MONDO:0002334	MONDO:0044881

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 94.

Phase distribution

Phase	Trials
PHASE2	33
PHASE1	32
PHASE1/PHASE2	20
PHASE3	5
Not specified	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03703375	PHASE3	ACTIVE_NOT_RECRUITING	Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
NCT01482962	PHASE3	COMPLETED	Alisertib (MLN8237) or Investigator’s Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma
NCT01796002	PHASE3	COMPLETED	Efficacy and Safety of Romidepsin CHOP vs CHOP in Patients With Untreated Peripheral T-Cell Lymphoma
NCT03355768	PHASE3	WITHDRAWN	Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCL
NCT03593018	PHASE3	COMPLETED	Efficacy and Safety of Oral Azacitidine Compared to Investigator’s Choice Therapy in Patients With Relapsed or Refractory AITL
NCT02393794	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
NCT03161223	PHASE1/PHASE2	RECRUITING	Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
NCT03278782	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Study of Pembrolizumab (MK-3475) in Combination With Romidepsin
NCT04747236	PHASE2	RECRUITING	Randomized Phase IIB Trial of Oral Azacytidine Plus Romidepsin Versus Investigator’s Choice in PTCL
NCT00007345	PHASE2	COMPLETED	Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
NCT00020202	PHASE2	COMPLETED	FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer
NCT00042822	PHASE2	COMPLETED	FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin’s Lymphoma
NCT00062075	PHASE2	COMPLETED	Romidepsin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
NCT00066638	PHASE2	COMPLETED	FR901228 in Treating Patients With Relapsed or Refractory Multiple Myeloma
NCT00077194	PHASE2	COMPLETED	FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00077337	PHASE2	COMPLETED	FR901228 in Treating Patients With Previously Treated Unresectable Locally Advanced or Metastatic Colorectal Cancer
NCT00079443	PHASE2	TERMINATED	FR901228 Alone or Combined With Rituximab and Fludarabine in Treating Patients With Relapsed or Refractory Low-Grade B-Cell Non-Hodgkin’s Lymphoma
NCT00084461	PHASE2	TERMINATED	Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
NCT00084682	PHASE2	COMPLETED	Depsipeptide in Unresectable Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck
NCT00085527	PHASE2	WITHDRAWN	FR901228 in Treating Patients With Relapsed or Refractory Advanced Ovarian Epithelial Cancer
NCT00085540	PHASE1/PHASE2	COMPLETED	FR901228 in Treating Patients With Recurrent High-Grade Gliomas
NCT00086827	PHASE2	COMPLETED	Romidepsin in Treating Patients With Relapsed Small Cell Lung Cancer
NCT00087295	PHASE2	TERMINATED	S0400, FR901228 in Treating Patients With Advanced Cancer of the Urothelium
NCT00091195	PHASE2	TERMINATED	Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer
NCT00098397	PHASE2	COMPLETED	FR901228 in Treating Patients With Metastatic Breast Cancer
NCT00098527	PHASE2	TERMINATED	FR901228 in Treating Patients With Refractory Stomach Cancer or Gastroesophageal Junction Cancer
NCT00098813	PHASE2	COMPLETED	Romidepsin in Treating Patients With Recurrent and/or Metastatic Thyroid Cancer That Has Not Responded to Radioactive Iodine
NCT00104884	PHASE2	TERMINATED	FR901228 in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
NCT00106301	PHASE2	COMPLETED	Continuation Trial Evaluating the Tolerability and Activity of FK228 in Patients That Completed Prior Study With FK228
NCT00106418	PHASE2	COMPLETED	A Research Study for Patients With Prostate Cancer
NCT00106613	PHASE2	COMPLETED	A Research Study for Patients With Metastatic Renal Cell Carcinoma
NCT00112463	PHASE2	COMPLETED	Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma
NCT00299351	PHASE2	UNKNOWN	A Multicenter, Open-Label Continuation Trial Evaluating the Tolerability and Activity of Depsipeptide (FK228) in Patients That Have Completed a Prior Clinical Study With Depsipeptide.
NCT00383565	PHASE2	TERMINATED	FR901228 in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma
NCT00426764	PHASE2	COMPLETED	A Trial of Romidepsin for Progressive or Relapsed Peripheral T-cell Lymphoma
NCT00431990	PHASE1/PHASE2	UNKNOWN	A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma
NCT00765102	PHASE2	TERMINATED	Trial of Romidepsin and Bortezomib for Multiple Myeloma
NCT01280526	PHASE1/PHASE2	COMPLETED	A Study of Escalating Doses of Romidepsin in Association With CHOP in the Treatment of Peripheral T-Cell Lymphomas
NCT01353664	PHASE2	COMPLETED	A Rollover Study for Patients Who Participated in Other Romidepsin Protocols
NCT01456039	PHASE1/PHASE2	COMPLETED	A Japanese Phase 1/2 Study to Assess the Efficacy, Safety and Pharmacokinetics of Romidepsin in Patients With Peripheral T-cell Lymphoma (PTCL)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

96 molecules share ≥1 primary target. Top 60 by shared-target count:

Molecule	Source	Status	Shared targets
BELINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
CELECOXIB	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
GIVINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
PANOBINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
PHENYLBUTANOIC ACID	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
SODIUM PHENYLBUTYRATE	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
VORINOSTAT	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
ABEXINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
CAFFEIC ACID	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
CURCUMIN	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
ENTINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
PRACINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
TACEDINALINE	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
TUCIDINOSTAT	ChEMBL	Phase 3	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
AR-42	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
CHLOROGENIC ACID	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
DACINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
FIMEPINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
NANATINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
QUISINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
Pazopanib	PubChem	Approved	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8, HDAC9
RICOLINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC7, HDAC8
BENDAMUSTINE	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC8
TINOSTAMUSTINE	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC4, HDAC5, HDAC6, HDAC8
CITARINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC6, HDAC7, HDAC8
BORTEZOMIB	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
MOCETINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC6, HDAC8
EBSELEN	ChEMBL	Phase 3	HDAC2, HDAC5, HDAC6, HDAC9
BUTYRIC ACID	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC8
DOMATINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC9
SODIUM BUTYRATE	ChEMBL	Phase 2	HDAC1, HDAC2, HDAC3, HDAC8
ATORVASTATIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC6
DAUNORUBICIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC6, HDAC8
LOVASTATIN	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2, HDAC6
BAICALEIN	ChEMBL	Phase 2	HDAC1, HDAC6, HDAC8
.gamma.-aminobutyric acid	PubChem	Approved	HDAC5, HDAC7, HDAC9
acetylcysteine	PubChem	Approved	HDAC5, HDAC7, HDAC9
Crizotinib	PubChem	Approved	HDAC1, HDAC2, HDAC6
VALPROIC ACID	ChEMBL	Phase 4 (approved)	HDAC1, HDAC2
MOLIBRESIB	ChEMBL	Phase 2	HDAC1, HDAC2
NICOXAMAT	ChEMBL	Phase 2	HDAC1, HDAC6
RESMINOSTAT	ChEMBL	Phase 2	HDAC1, HDAC6
Gefitinib	PubChem	Approved	HDAC5, HDAC9
Idelalisib	PubChem	Approved	HDAC1, HDAC6
ABAMETAPIR	ChEMBL	Phase 4 (approved)	HDAC6
ATALUREN	ChEMBL	Phase 4 (approved)	HDAC6
AXITINIB	ChEMBL	Phase 4 (approved)	HDAC6
BUFEXAMAC	ChEMBL	Phase 4 (approved)	HDAC6
EVANS BLUE FREE ACID	ChEMBL	Phase 4 (approved)	HDAC6
EXIFONE	ChEMBL	Phase 4 (approved)	HDAC1
FEBUXOSTAT	ChEMBL	Phase 4 (approved)	HDAC6
FLUPHENAZINE	ChEMBL	Phase 4 (approved)	HDAC6
GENTIAN VIOLET	ChEMBL	Phase 4 (approved)	HDAC6
INDOPROFEN	ChEMBL	Phase 4 (approved)	HDAC6
MARIBAVIR	ChEMBL	Phase 4 (approved)	HDAC6
MOMELOTINIB	ChEMBL	Phase 4 (approved)	HDAC1
MONOBENZONE	ChEMBL	Phase 4 (approved)	HDAC6
NITAZOXANIDE	ChEMBL	Phase 4 (approved)	HDAC6
PHENYL AMINOSALICYLATE	ChEMBL	Phase 4 (approved)	HDAC6
PIPERACETAZINE	ChEMBL	Phase 4 (approved)	HDAC6